Whitehawk Therapeutics IncWHWK
Price$3.76Intrinsic value$3.3710% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $7.1M-72.5% YoYTTM through 30 Jun 2026
Net Income -$20.6MTTM through 30 Jun 2026
Free Cash Flow -$69.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-1,601.1%
Net Margin-288.3%

Returns

-68.5%ROE
-42.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio11.36x
Net Debt-$123Mnet cash position
Cash & Equivalents$85.2M

Quality Metrics

Altman Z-Score8.87
Piotroski F-Score2 / 9
FCF Margin-970.6%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $7.1M
Diluted EPS-$1.21TTM
'21'22'23'24'25
FY2025: $-0.33

Dividend

No dividend

Capital Allocation

R&D Spend$63.5M
Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.